Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-0415 in Virologically Suppressed HIV-1
NCT07719491Phase 1Recruiting
- Sponsor
- Gilead Sciences
- Start
- Jul 2026
- Primary completion
- Aug 2029
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of GS-0415 in human immunodeficiency virus type 1 infection (HIV-1) (6 arms), sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants Experiencing Treatment-Emergent Adverse Events at 99 days, Percentage of Participants Experiencing Clinical Laboratory Abnormalities at 99 days and 4 more. Started Jul 2026; status: recruiting.
02
Drugs
GS-0415
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT07719491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07719491.